Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: J Thorac Oncol. 2014 Aug;9(8):1101–1110. doi: 10.1097/JTO.0000000000000214

Figure 2. A-C. MV infects and lyses NSCLC cells in vitro.

Figure 2

A) Cell viability assay of cells treated with MV-GFP after 72 hours of treatment. Immortalized bronchial epithelial cells (HBEC and Beas2B) are used as a non-malignant control. (MOI = multiplicity of infection). Data are expressed as a percentage of untreated cells. B) Fluorescence microscopy of cells 72 hours following treatment with MV-GFP at MOI of 1.0 demonstrating fluorescent syncitia. Corresponding light microscopy photographs are shown. C) Human CEA measurement from supernatants of MV-infected NSCLC cells. Supernatants were collected 48 hours after infection of cells and measured by ELISA assay (CEA=carcinoembryonic antigen). Error bars indicate standard deviation of the mean.